drugset / Trial / NCT00193375
Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer
Phase 2
Completed
60 enrolled
SCRI Development Innovations, LLC
Genentech, Inc. · collabPharmacia and Upjohn · collab
NaSingle-groupOpen-labelTreatment
Summary
In this multicenter trial, we plan to evaluate the feasibility and toxicity of initial treatment with irinotecan/carboplatin/radiation therapy, followed by treatment with bevacizumab, in patients with limited stage small cell lung cancer.
Timeline
- Start
- 2003-08
- Primary completion
- 2008-04
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Irinotecan | Small molecule | 50 mg/m2 | Intravenous |